Blood pool contrast extends MRA's ability
The diagnostic capability of MR angiography is directly related to the application of gadolinium-enhanced imaging, said Dr. Thomas Grist, chief of MRI at the University of Wisconsin Medical School in Madison.
The diagnostic capability of MR angiography is directly related to the application of gadolinium-enhanced imaging, said Dr. Thomas Grist, chief of MRI at the University of Wisconsin Medical School in Madison.
Gd-enhanced MRA has some complexities, however, associated with image acquisition and limited spatial resolution/coverage. A different approach will soon be available, as several investigational blood pool contrast agents are under investigation.
Blood pool agents fit into two categories. One is macromolecular contrast agents, which are large molecules that clear from the blood stream relatively slowly. These include gadomer-17 and P792. The other alternative is protein-binding agents such as MS-325 and B22956.
Because the spatial resolution that may be achieved with MRA is directly proportional to the length of the acquisition, high-resolution images can be acquired with blood pool agents in regions of the body with no respiratory motion, Grist said. The long blood half-life also allows for reexamination of vascular territories that may be inadequately imaged on the initial first-pass MRA exam, although these extended acquisition methods require image processing techniques that suppress signal from the venous structures enhanced by blood pool agents.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
